A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
Status:
Unknown status
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
TQB3616 may work in cancer by stopping cancer cells from multiplying.TQB3616 is in a new
class of drugs called CDK inhibitors.This research study is the first time that TQB3616 will
be given to people.TQB3616 is taken by mouth daily.